Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Japan flag Japan · Delayed Price · Currency is JPY
4,005.00
-5.00 (-0.12%)
Jul 8, 2025, 3:30 PM JST
6.91%
Market Cap 292.58B
Revenue (ttm) 156.01B
Net Income (ttm) 21.76B
Shares Out 72.96M
EPS (ttm) 295.15
PE Ratio 13.59
Forward PE 12.44
Dividend 90.00 (2.25%)
Ex-Dividend Date Aug 28, 2025
Volume 223,400
Average Volume 153,735
Open 3,992.00
Previous Close 4,010.00
Day's Range 3,964.00 - 4,021.00
52-Week Range 3,708.00 - 4,735.00
Beta 0.38
RSI 38.41
Earnings Date Jul 10, 2025

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United St... [Read more]

Sector Healthcare
Founded 1847
Employees 2,799
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4530
Full Company Profile

Financial Performance

In 2024, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.

Financial Statements

News

There is no news available yet.